{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:31:52Z","timestamp":1793298712048,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-025-01029-9","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:24:46Z","timestamp":1758810286000},"page":"378-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lymph node dissection based on 18F-PSMA PET\/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study"],"prefix":"10.1038","volume":"29","author":[{"given":"Zhuo","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songliang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Ci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4036-9470","authenticated-orcid":false,"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"1029_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","volume":"72","author":"N Fossati","year":"2017","unstructured":"Fossati N, Willemse PPM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol. 2017;72:84\u2013109.","journal-title":"Eur Urol"},{"key":"1029_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","volume":"48","author":"BHE Jansen","year":"2021","unstructured":"Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, et al. Pelvic lymph-node staging with 18F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial. Eur J Nucl Med Mol Imaging. 2021;48:509\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1029_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","volume":"79","author":"JFP Lestingi","year":"2021","unstructured":"Lestingi JFP, Guglielmetti GB, Trinh QD, Coelho RF, Pontes J, Bastos DA, et al. Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial. Eur Urol. 2021;79:595\u2013604.","journal-title":"Eur Urol"},{"key":"1029_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.eururo.2013.03.053","volume":"65","author":"KA Touijer","year":"2014","unstructured":"Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. 2014;65:20\u20135.","journal-title":"Eur Urol"},{"key":"1029_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jss.2009.05.004","volume":"167","author":"T Cai","year":"2011","unstructured":"Cai T, Nesi G, Tinacci G, Giubilei G, Gavazzi A, Mondaini N, et al. Clinical importance of lymph node density in predicting outcome of prostate cancer patients. J Surg Res. 2011;167:267\u201372.","journal-title":"J Surg Res"},{"key":"1029_CR6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.eururo.2013.05.026","volume":"65","author":"B Yuh","year":"2014","unstructured":"Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014;65:918\u201327.","journal-title":"Eur Urol"},{"key":"1029_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s00259-025-07133-1","volume":"52","author":"EV Li","year":"2025","unstructured":"Li EV, Schaeffer EM, Ramesh Kumar SKS, Zhou R, Yang XJ, Mana-Ay M, et al. Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy. Eur J Nucl Med Mol Imaging. 2025;52:2335\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1029_CR8","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00345-020-03490-8","volume":"39","author":"YJL Bodar","year":"2021","unstructured":"Bodar YJL, Jansen BHE, van der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, et al. Detection of prostate cancer with 18F-DCFPyL PET\/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial. World J Urol. 2021;39:2439\u201346.","journal-title":"World J Urol"},{"key":"1029_CR9","unstructured":"Initial multicentre experience of 68 gallium-PSMA PET\/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited - PubMed [Internet]. [2025]. https:\/\/pubmed.ncbi.nlm.nih.gov\/28548372\/"},{"key":"1029_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bju.14506","volume":"124","author":"PJ van Leeuwen","year":"2019","unstructured":"van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, et al. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)\/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer. BJU Int. 2019;124:62\u20138.","journal-title":"BJU Int"},{"key":"1029_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206:52\u201361.","journal-title":"J Urol"},{"key":"1029_CR12","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635\u201342.","journal-title":"JAMA Oncol"},{"key":"1029_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00259-014-2915-3","volume":"42","author":"T Krohn","year":"2015","unstructured":"Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1029_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-017-0133-5","volume":"17","author":"A Iravani","year":"2017","unstructured":"Iravani A, Hofman MS, Mulcahy T, Williams S, Murphy D, Parameswaran BK, et al. 68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. Cancer Imaging. 2017;17:31.","journal-title":"Cancer Imaging"},{"key":"1029_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.2967\/jnumed.120.251447","volume":"62","author":"M Kroenke","year":"2021","unstructured":"Kroenke M, Mirzoyan L, Horn T, Peeken JC, Wurzer A, Wester HJ, et al. Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET\/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity. J Nucl Med. 2021;62:1082\u20138.","journal-title":"J Nucl Med"},{"key":"1029_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1029_CR17","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","volume":"45","author":"A Afshar-Oromieh","year":"2018","unstructured":"Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2045\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1029_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"A Stabile","year":"2022","unstructured":"Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, et al. Can negative prostate-specific membrane antigen positron emission tomography\/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol. 2022;5:1\u201317.","journal-title":"Eur Urol Oncol"},{"key":"1029_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.14828","volume":"124","author":"JW Yaxley","year":"2019","unstructured":"Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124:401\u20137.","journal-title":"BJU Int"},{"key":"1029_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.eururo.2022.06.002","volume":"82","author":"G Gandaglia","year":"2022","unstructured":"Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F, et al. Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: results of a planned interim analysis of a prospective phase 2 study. Eur Urol. 2022;82:411\u20138.","journal-title":"Eur Urol"},{"key":"1029_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2967\/jnumed.123.266495","volume":"65","author":"MGM Schilham","year":"2024","unstructured":"Schilham MGM, Somford DM, K\u00fcsters-Vandevelde HVN, Hermsen R, van Basten JPA, Hoekstra RJ, et al. Prostate-specific membrane antigen-targeted radioguided pelvic lymph node dissection in newly diagnosed prostate cancer patients with a suspicion of locoregional lymph node metastases: the DETECT trial. J Nucl Med. 2024;65:423\u20139.","journal-title":"J Nucl Med"},{"key":"1029_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/706309","volume":"2012","author":"SG Joniau","year":"2012","unstructured":"Joniau SG, Van Baelen AA, Hsu CY, Van Poppel HP. Complications and functional results of surgery for locally advanced prostate cancer. Adv Urol. 2012;2012:706309.","journal-title":"Adv Urol"},{"key":"1029_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bju.15881","volume":"131","author":"D Meijer","year":"2023","unstructured":"Meijer D, Ettema RH, van Leeuwen PJ, van der Kwast TH, van der Poel HG, Donswijk ML, et al. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer. BJU Int. 2023;131:330\u20138.","journal-title":"BJU Int"},{"key":"1029_CR24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/cancers13050948","volume":"13","author":"S Kimura","year":"2021","unstructured":"Kimura S, Urabe F, Sasaki H, Kimura T, Miki K, Egawa S. Prognostic significance of prostate-specific antigen persistence after radical prostatectomy: a systematic review and meta-analysis. Cancers. 2021;13:948.","journal-title":"Cancers"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01029-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01029-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01029-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:41:45Z","timestamp":1779331305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01029-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01029-9","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the contributing authors have any conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent prior to their participation in the study. The trial was approved by the Institutional Ethics Board of PLA General Hospital, and the protocol was reviewed by the Scientific Committee of the Chinese Clinical Trial Registry (ChiCTR2200063256).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}